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Genome wide association studies have identified several genes that might be associated
with increase susceptibility to Type 1 Diabetes (T1D) and Crohn’s disease. Both Crohn’s
disease and T1D have a profound impact on the lives of patients and it is pivotal to
investigate the genetic role in patients acquiring these diseases. Understanding the effect
of single nucleotide polymorphisms (SNP’s) in key genes in patients suffering from T1D
and Crohn’s disease is crucial to finding an effective treatment and generating novel
therapeutic drugs. This review article is focused on the impact of SNP’s in PTPN2 (protein
tyrosine phosphatase, non-receptor type 2) and PTPN22 (protein tyrosine phosphatase
non-receptor type 22) on the development of Crohn’s disease and T1D. The PTPN2
gene mutation in T1D patients play a direct role in the destruction of beta cells while
in Crohn’s disease patients, it modulates the innate immune responses. The PTPN22
gene mutations also play a role in both diseases by modulating intracellular signaling.
Examining the mechanism through which these genes increase the susceptibility to both
diseases and gaining a better understanding of their structure and function is of vital
importance to understand the etiology and pathogenesis of Type 1 Diabetes and Crohn’s
disease.
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INTRODUCTION
Type 1 Diabetes
Type 1 Diabetes (T1D) is a chronic metabolic disorder that accounts for 5–10% of all diabetic cases.
The incidence rate of T1D is steadily increasing and predicted to double in children under the
age of 5 by 2020 (Todd, 2010). It has been suggested that T1D is a result of interplay between
genetic predisposition, environmental factors, and reprograming of the immune system (Figure 1;
Hober and Sauter, 2010). Regardless of the etiological factors of T1D, it is well-accepted that
the destruction of pancreatic beta cells affects the level of insulin secretion leading to disease
development. Destruction of pancreatic beta cells is mediated by an altered immune response due
to genetic anomalies resulting in increase of pro-inflammatory cytokines and auto-reactive T and B
lymphocytes. The impact of insulin deficiency includes hyperglycemia, ketoacidosis, kidney failure,
heart disease, stroke, and possibly death (Naser et al., 2013).
Several environmental factors have been proposed to play a role in the development of T1D. This
include diet, enteroviruses, and bacteria such asMycobacterium avium subspecies paratuberculosis
(MAP; van Belle et al., 2011). Vitamin D deficiency has been proposed to play a role in
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FIGURE 1 | Interplay between genetic predisposition, environmental
factors, and the immune system in Crohn’s disease and T1D.
reprograming the immune system leading to pre-sensensitization
to self-antigens (van Belle et al., 2011). The role of enteroviruses
in T1D pathogenesis has been linked to upregulation of IFNα
levels causing pancreatic beta cell damage (van Belle et al., 2011).
Most recently, MAP has also been proposed. Naser et al. has
demonstrated a high degree of homology (44% homology and
75% similarity over 16 amino acid sequences—potential epitope
sites) between human pancreatic glutamic acid decarboxylase
65 kDa (GAD65) and MAP heat shock protein 65 kDa (Hsp65;
Naser et al., 2013). The molecular mimicry between host GAD65,
and the bacterial Hsp65 leads to reprograming of the immune
system, and retargeting of host cells by pro-inflammatory
cytokines and resulting in activation of autoantigen (Burn et al.,
2011).
Crohn’s Disease
Crohn’s disease is an inflammatory bowel disease (IBD) that is
characterized by transmural inflammation of the intestinal wall,
which may occur at different sites of the gastrointestinal tract
(Scharl et al., 2009). IBD prevalence is rapidly increasing at
an alarming rate. In a recent epidemiologic study in the State
of Florida, United States, it was estimated that the prevalence
of CD is 222 per 100,000 persons and the prevalence of UC
is 307 per 100,000 persons in Florida. The prevalence of IBD
was higher among people ages 30–80 years old, non-Hispanic
Whites and females (Francois, 2006). The literature is enriched
with reports suggesting that Crohn’s disease, like T1D, is caused
by multiple factors including genetic anomalies, environmental
factors, and immune system malfunctions (Figure 1). The latter
has significant impact on the pathophysiology of the disease
including gut microbiota (Scharl et al., 2009). GWAS have
shown that several candidate genes may cause an increase in
the susceptibility to developing Crohn’s disease (Barrett et al.,
2008). These genes include: NOD2, ATG16L1, IL23R, IRGM,
CCR6, PTPN2, and PTPN22 (Figure 2; Barrett et al., 2008).
Environmental factors that have been associated with Crohn’s
disease include pathogenic Escherichia coli strains, MAP, and
FIGURE 2 | Venn diagram of known susceptibility loci associated with
both T1D and Crohn’s disease.
others (Nazareth et al., 2015). Naser et al. has shown that MAP
was found in the blood and breast milk of patients with Crohn’s
disease (Naser et al., 2000, 2004). Excessive secretion of pro-
inflammatory cytokines and aberrant T cell differentiation have
also exacerbated Crohn’s disease, resulting in loss of tolerance,
and intestinal dysbiosis (Sartor, 2006).
Common Genes Associated with Type 1
Diabetes and Crohn’s Disease
Genome-wide association studies (GWAS) have identified many
genes to be involved in the development of Crohn’s disease
or T1D or both. Most often, the mutation is due to a single
nucleotide polymorphism (SNP) resulting in immune system
impairment and ultimately increased susceptibility to disease.
The susceptibility genes implicated to have a role in T1D
pathogenesis include INS, HLA, PTPN2, PTPN22, IL-10, IFIH1,
and CTLA4 (Figure 2; van Belle et al., 2011; Naser et al., 2013).
The potential role of some of these genetic mutations have been
examined in previous studies, but themechanisms by which these
mutated genes play a role in T1D is still unclear and require
further research.
GWAS have also suggested a possible association between
other candidate genes and other diseases. Recently, two possible
candidate genes that have been examined showed mutations
in Crohn’s disease and T1D. These genes are PTPN2 (protein
tyrosine phosphatase non-receptor type 2) and PTPN22 (protein
tyrosine phosphatase non-receptor type 22; Table 1; Scharl et al.,
2012a). The PTPN2 gene mutation in T1D patients plays a direct
role in the destruction of beta cells, while in Crohn’s disease
patients, it modulates the innate immune responses (Barrett et al.,
2008; Espino-Paisan et al., 2011). The PTPN22 gene mutations
also play a role in both diseases by modulating intracellular
signaling (Barrett et al., 2008). PTPN2 and PTPN22 genes both
encode for tyrosine phosphatases (PTPs) signalingmolecules that
modulate and regulate a variety of cellular processes such as cell
growth, differentiation, mitotic cycle, oncogenic transformation,
and survival (Estus et al., 2013). Studies have shown that PTPs
in general are key regulators of signaling transduction. Most
cells of the immune system show high expression of tyrosine
phosphorylation and express more PTP genes than other tissues
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TABLE 1 | Comparative analysis of the two protein tyrosine phosphatases
associated with Type 1 Diabetes and Crohn’s disease.
PTPN2 PTPN22
Location (Espino-Paisan
et al., 2011)
Chromosome loci 18p11 Chromosome loci 1p13
Isoforms (Cerosaletti and
Buckner, 2012)
Two major alternative
splicing Endosplasmic
reticulum and nucleus
Different: alternative
splicing Cytoplasm
C-terminus domain
(Cerosaletti and Buckner,
2012)
Variable Long non-catalytic
chain with several
proline rich motif
N-terminus domain
(Cerosaletti and Buckner,
2012)
Conserved catalytic Phosphatase
SNP/rsID (T1D/CD; Barrett
et al., 2008; Espino-Paisan
et al., 2011)
Rs2542151-G variant
allele
Rs2476601 R620W
variant allele
Significant P-value for T1D
Pathogenesis (Barrett et al.,
2008; Smyth et al., 2008)
3.6× 10−15 1.13× 10−88
Significant P-value for CD
Pathogenesis (Barrett et al.,
2008; Smyth et al., 2008)
5.10× 10−17 6.6× 10−6
Legend: PTPN2, protein tyrosine phosphatase non-receptor type 2 gene; PTPN22,
protein tyrosine phosphatase non-receptor type 22 gene; SNP, single nucleotide
polymorphism; T1D, Type 1 Diabetes; CD, Crohn’s disease.
in the body. In fact, a distinct phenotype exists among PTP-
knockout mice having deficient or hyperactive immune status
with severe abnormalities in hematopoiesis. This suggests a
crucial role of PTP in maintaining a balanced immune system
(Chistiakova, 2010). Predisposing variants in these genes can
potentially lead to a less efficient suppression of inflammatory
response due to a reduced amount of negative regulation,
which may contribute to diseases such as T1D and Crohn’s
disease.
GENETIC VARIATIONS OF PTPN2 AND
PTPN22
PTPN2 Role in Type 1 Diabetes and Crohn’s Disease
The PTPN2 is located on chromosome 18 and is a member of the
PTP family, which dephosphorylates receptor protein tyrosine
residues and regulates many signaling pathways and processes.
The protein has two major isoforms—one in the endoplasmic
reticulum (48 kD) and the other in the nucleus (45 kD). PTPN2
is produced by alternative splicing and share a highly conserved
PTP catalytic domain but different C-terminus (Cerosaletti and
Buckner, 2012). PTPN2 expression plays an important role in
regulating signal transduction and it is of pivotal importance
to the pathogenesis of many diseases such as T1D and Crohn’s
disease.
GWAS have showed that PTPN2 is a T1D susceptibility gene
and risk locus for Crohn’s disease. In T1D, the association
was obtained from chromosome region 18p11, which showed
an associated risk variant at SNP rs2542151-G allele (Espino-
Paisan et al., 2011). The involvement of the PTPN2 gene in
T1D is complex due to its ubiquitous expression which may
play a role in beta cell apoptosis (Santin et al., 2011). This
modulation occurs after exposure to type I (IFNα and IFNβ) and
Type II interferon (IFNγ), which lead to beta cells loss in early
T1D. Moreover, the study indicated that local IFN production
interacts with PTPN2 expression and induces a malfunctioning
pro-apoptotic activity of Bim, a BH3-only protein (Santin et al.,
2011). Bim is a member of the beta cell lymphoma two protein
family (Bcl-2) that mediates apoptosis by activating Bax and Bak.
This ultimately results in an increase of beta cell death via JNK
activation and intrinsic apoptotic pathways (Santin et al., 2011).
Many of T1D susceptibility genes are expressed in pancreatic
beta cells indicating a possible self-destruction if these genes were
mutated. The decrease of beta cell mass is driven in part by the
release of cytokines and chemokines from immune cells. PTPN2
is a negative regulator of the JAK-STAT signaling pathway, which
is activated downstream by IFN receptors. Studies have shown
that PTPN2 gene knockdown exacerbates type I and II IFN-
induced beta cell death by inducing BAX translocation to the
mitochondria after subsequent exposure to type I and II IFNs.
This occurs because when PTPN2 is mutated or knockdown,
there is less of a negative regulation of apoptotic processes,
thus, increasing the signaling of the destruction of cells. This
reaction also releases cytochrome c and activates caspase three
in human beta cells, which both induce apoptosis. Along with
these reactions, there is an increase of Bim phosphorylation,
which is regulated by JNK1 that also induces apoptosis of the β-
cells. While examining this signaling cascade, PTPN2 expression
seems to be a putative factor in beta cell apoptosis (Santin et al.,
2011). These findings imply that along with a genetic variation,
the production of local IFN can lead to beta cell apoptosis as well
as clarify the interplay between candidate genes and apoptosis in
beta cells.
Recently, the role of PTPN2 in pancreatic endocrine function
and insulin secretion was explored. In a study by Xi et al.
the deficiency in PTPN2 expression by knockout affected beta
cell function in mice (Xi et al., 2015). The reduced insulin
secretion wass associated with a decreased insulin content and
glucose sensing, which showed that STAT3 could be a relevant
target for the PTPN2 phosphatase regulation in the pancreas (Xi
et al., 2015). PTPN2 regulates insulin signaling by inactivating
its receptor through de-phosphorylation of the insulin receptor
β-chain in conjunction with the PTP1B phosphatase. This
regulates gluconeogenesis in the liver by attenuating STAT3
signaling, which decreases glucose levels (Fukushima et al.,
2010; Cerosaletti and Buckner, 2012). A deficiency of PTPN2
expression will lead to a cytokine-induced beta cell apoptosis of
the pancreatic cells after inducing the mitochondrial apoptotic
pathway along with impacting glucose homeostasis/utilization
(Fukushima et al., 2010; Cerosaletti and Buckner, 2012). With
these two systems out of control, T1D could occur in patients
who have a mutation in the PTPN2 gene.
With the help of CD4+ helper T cells, CD8+ cytotoxic T cells
are the primary mediators of beta cell destruction via secretory
(perforin/granzyme) or Fas mediated pathways. Wiede et al.
showed that a variant in PTPN2 (rs1893217) in mice greatly
increases T cell receptor signaling, which can lead to reduced
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self-antigen tolerance due to decreased negative regulation
(Wiede et al., 2014). With this occurring, the response after self-
antigen presentation could cause destruction of beta cells (Wiede
et al., 2014). Moreover, the risk variant rs1893217 in the PTPN2
gene is associated with a reduction in the receptor signaling of IL-
2, which alters expression of FOXP3+ T regulatory cells (Tregs)
in T1D patients (Cerosaletti and Buckner, 2012). Tregs are a
group of T cells that modulate the immune system homeostasis
by maintaining tolerance to self-antigens. They also prevent
autoimmune diseases by acting as suppressors to the immune
response. This dysregulation of FOXP3+ Tregs leads to both T
cells and B cells being unregulated due to FOXP3+ Treg cells
suppressing their activation (Cerosaletti and Buckner, 2012).
With these altered FOXP3+ Tregs, over reactivity of both T
cells and B cells could cause self-antigens to be recognized as
foreign (Cerosaletti and Buckner, 2012). It explains how genetic
variations in PTPN2 could lead to the development of T1D
due to the deregulation of Tregs homeostasis (Cerosaletti and
Buckner, 2012). A SNP mutation (rs2542151-G) in the PTPN2
gene is found not only in T1D, but in Crohn’s disease as well
(Espino-Paisan et al., 2011). In Crohn’s disease, SNP variation
in the PTPN2 gene influences susceptibility to the disease and
mechanism of pathogenesis.
It is a fact that epithelial barrier dysfunction coincides with
immune response dysregulation in Crohn’s disease. PTPN2
regulates intestinal epithelial barrier function and is activated
by IFNγ which is up regulated by TNFα in intestinal epithelial
cells (IEC; Osterman and Lichtenstein, 2007; McCole, 2012;
Spalinger et al., 2015). IFNγ is an effector cytokine for Th-1
and potentially Th17-propagated immune responses (McCole,
2012; Spalinger et al., 2015). TNFα is a key effector of Cohn’s
disease in humans; therefore, anti-TNFα therapy is an effective
treatment option for patients (Osterman and Lichtenstein, 2007).
Scharl et al. showed that PTPN2 gets activated by IFNγ and in
turn, it limits the pro-inflammatory cytokine-induced signaling
and barrier defects. IFNγ plays a role in Crohn’s pathogenesis
and is noted to increase the permeability of intestinal epithelial
barrier (Scharl et al., 2009). IFNγ is involved in tissue destruction
and possibly, in reduction of barrier functions as a result of
reconfigured tight junctions. PTPN2 usually protects the barrier
by reducing its permeability and prevent induction of pore
forming protein claudin-2. Claudin-2 is part of a family of
proteins that regulates paracellular permeability and functions as
sealer-like in tight junctions. Expressions or localization changes
in claudins result in increased barrier permeability (Scharl
et al., 2009). Recent study showed that claudin-2 upregulation
in Crohn’s disease increased number of tight junction strand
breakages (McCole, 2012). PTPN2 expression plays a role in
the regulation of inflammatory response, as loss of it leads to
a severe IFNγ signaling cascade, leading to problems in the
intestinal epithelial barrier function. PTPN2 has an important
role in cytokine signaling of immune cells by inactivating STAT1
and STAT3; the loss of PTPN2 enhances STAT phosphorylation
(Scharl et al., 2009). This evidence shows the importance in
how a mutation altering function of the PTPN2 gene could
lead to deleterious effects and may explain the pathogenesis of
associated diseases.
Loss of PTPN2 expression is associated with increased
expression and secretion of pro-inflammatory mediators in the
intestinal epithelium (Scharl et al., 2009). As previously stated,
there is an aberrant T cell differentiation and intestinal dysbiosis
in Crohn’s disease, which PTPN2 seems to play a role in. It is
very important to regulate T helper (Th) cell differentiation into
effector T cell populations to maintain tolerance toward self-
antigens and commensal bacteria of the intestine. There is a
potential role of the PTPN2 protein in regulating differentiation
of CD4+ Th cells into its subset population. A loss of the PTPN2
protein in T cells results in a disease promoting state. Loss of
PTPN2 in T cell compartments leads to enhanced induction
of Th1 and Th17 cells while having an impaired induction of
regulatory T cells (Spalinger et al., 2015). In several mousemodels
as shown by Spalinger et al. increased inflammation occurred as a
result of high numbers of Th1 and Th17 cells due to the loss of the
PTPN2 protein function (Spalinger et al., 2015). Consequently,
there is a disturbed immune response and altered intestinal
microbiota in Crohn’s disease that ultimately play a major role
in its pathogenesis. Secretion of specific cytokines allows the Th
cells to alter the immune response to commensal and pathogenic
bacteria, and in doing so; it has a huge impact in the makeup of
the intestinal microbiota (Spalinger et al., 2015). These studies
further support the pivotal role of the PTPN2 gene in Crohn’s
disease and the deleterious effects of a mutation within it.
PTPN2 also plays a role in autophagosome formation in
human intestinal cells. Autophagy is an essential process
for maintaining cell homeostasis, survival, and modulating
inflammation. Studies have shown that knockdown of PTPN2
caused impaired autophagosome formation and dysfunctional
autophagy resulting in response to TNFα and IFNγ. Moreover,
silencing PTPN2 in vitro exacerbates intestinal epithelial barrier
dysfunction when exposed to IFNγ (Scharl et al., 2012b).
Impairment in this gene shows that the pathway that leads to
the perpetual intestinal inflammation is associated with Crohn’s
disease patient. Loss of PTPN2 expression can also lead to
an increase in cytokine-induced mTOR phosphorylation, which
leads to a decrease in autophagy. It was reported that PTPN2
deficiency leads to a reduction of expression of autophagy
genes that include: beclin 1, ATG7, ATG5, ATG12 conjugates,
and ATG16L1 (Scharl and Rogler, 2012; Scharl et al., 2012b).
Consequently, this leads to low amounts of autophagy proteins
that create an abnormal autophagosome in the intestinal cells
(McCole, 2012).
PTPN2 expression is very important in immune regulation
as can be noted with PTPN2 deficient mice that suffer severe
inflammation and die swiftly after birth. A balance between
inflammatory and regulatory T cells should be maintained for
optimal tolerance and protection against pathogens (Spalinger
et al., 2015). These observations show that the presence of the
risk variants such as rs2542151-G within the PTPN2 gene in
Crohn’s disease cause disease-associated characteristics (Espino-
Paisan et al., 2011). The mutation in PTPN2 could not only cause
Crohn’s disease but also T1D due to the presence of this mutation
in both disease states. With this unregulated immune system
due to the loss of PTPN2 function, cytokines that play a role in
inflammation are substantially increased, and T cells/B cells begin
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to react to self-antigens. These changes will not only affect beta
cells of the pancreas but should also affect the intestinal walls
of these genetically susceptible patients, thus, they could cause
either T1D or Crohn’s disease.
PTPN22 Role in Type 1 Diabetes and Crohn’s Disease
The PTPN22 gene is located on chromosome 1p13 which is a
member of the PTPs that negatively regulate T-cell activation
(Cerosaletti and Buckner, 2012). The encoded protein is a
lymphoid specific intracellular phosphatase that associates with
the molecular adapter protein CBL. PTPN22 has alternatively
spliced transcript variants encoding several distinct isoforms.
It is located in the cytoplasm, and consists of an N-terminal
phosphatase domain and a long non-catalytic C terminal with
several proline rich motifs. PTPN22 dephosphorylates kinases
Lck, Fyn, and ZAP70, which are all involved in T-cell signaling
(Cerosaletti and Buckner, 2012). A SNP mutation (rs2476601)
in PTPN22 is associated with T1D and Crohn’s disease (Barrett
et al., 2008). Variants within these genes lead to the development
of an abnormal immune response. PTPN22 SNPmutation causes
a single substitution of arginine for tryptophan in the encoded
protein (R620W) leading to a decrease in T cell receptor and B
cell receptor signaling (Menard et al., 2011). This may ultimately
result in an unbalanced establishment of tolerance in both T cells
and B cells (Menard et al., 2011).
In B cells, PTPN22 risk variant (R620W) prevents the removal
of developing auto-reactive B cells. Menard et al. showed that
new mature naive B cells from carriers of this variant had
higher frequencies of auto-reactive clones as opposed to non-
carriers (Menard et al., 2011). This demonstrates defective
central and peripheral B cell tolerance checkpoints leading to
the development of the previously mentioned auto-reactive B
cells. To be noted, there are essentially two methods to removing
autoreactive B cells. First, a central tolerance checkpoint is
done to remove most of the developing B cells expressing
polyreactive antibodies in the bone marrow (Wardemann et al.,
2003). Second, a peripheral tolerance checkpoint is done in
order to counter select autoreactive new B cells before entering
compartments designed for mature naive B cell (Wardemann
et al., 2003). This shows that a single risk allele would have
a dominant effect of changing auto-reactive B cell counter-
selection before onset of any autoimmunity. With regards to
the decrease in T cell receptor signaling, it is possible that the
T cell selection occurring in the thymus and T-regs in general,
will be affected by this risk variant as well. Menard et al. also
performed gene array experiments on mature naive B cells with
the risk variant and found an upregulation of genes such asCD40,
TRAF1, and IRF5 (Menard et al., 2011). These genes encode
proteins promoting B cell activation and are susceptibility genes
of many deregulated immune diseases. They concluded that the
association of the PTPN22 gene with autoimmunity is due to
impaired removal of auto-reactive B cells and the upregulation
of the genes mentioned above (Menard et al., 2011).
In T cells, PTPN22 is directly involved in threshold setting
for T cell receptor signaling (Vang et al., 2005). PTPN22 SNP
mutation results in a phosphatase with a higher catalytic activity
and a more potent negative regulation of T cell lymphocyte
activation (Vang et al., 2005). Recent studies on PTPN22
knockout mice suggested that the increase risk of developing
autoimmune diseases could occur through alterations of the
periphery Treg cells while PTPN22 knockout increases the
thymic selection of Treg cells (Maine et al., 2012). Both Wu
et al. and Zheng et al. also reported a “gain-of-function” model
of Treg cell selection, where even though PTPN22 knockout did
have reduced TCR signaling, they did not have an impairment of
their ability to negatively select autoreactive T cells in the thymus
(Zheng and Kissler, 2013; Wu et al., 2014). Overall, PTPN22 SNP
mutation does not necessarily affect Treg cells, but could possibly
affect other T cells once they leave out of the thymus or even
have other effects on the immune system. Even though the role
of PTPN22 mutation is still debatable, both models (“gain-of-
function”) and (“loss-of-function”) can still play a role in the
development of T1D. The “gain-of-function” model does show
that there is an increase in T cell activity, but this increase of
mature T cell activation could be activated due to the loss of self-
tolerance of peripheral T cells.With the “loss-of-function”model,
it shows that if PTPN22 is knocked out or mutated, then there is
a loss of self-tolerance earlier on in the T cell life, which can then
be activated by self-antigens.
PTPN22 expression could potentially influence immuno-
receptors, which could explain how it contributes to the
development of diseases. Immuno-receptor signaling is governed
by Src and Syk kinases, which are substrates of the PTPN22
protein (van Belle et al., 2011). A function of PTPN22 is to
downregulate T-cell signaling by interacting with its negative
regulatory kinase, C-terminal Src tyrosine kinase or Csk. A
mutation of the PTPN22 gene ends up encoding products with
different Csk binding affinities (Ladner et al., 2005). The R620W
substitution decreases the ability of the phosphatase to bind to
the SH3 domain of Csk, thus, showing how PTPN22 expression
is associated with T cell signaling pathways. PTPN22 C1858T
SNP, which results in R620W substitution in the encoded protein,
creates diabetes-specific autoimmunity. This can be used as
a marker for disease progression by the noted appearance of
autoantibodies. PTPN22 SNP mutation seems to be associated
with insulin-specific humoral autoimmunity (Hermann et al.,
2006). Earlier studies reported that carriers of the risk allele are
younger at the time of diagnosis of T1D, whereas PTPN22 gene is
a predictor of a more rapid progression of the disease (Hermann
et al., 2006). Overall, PTPN22 SNP contributes to failure in
tolerance, which leads to the development of autoantibodies and
subsequently, the disease (Cerosaletti and Buckner, 2012).
GWAS have also shown that SNP risk variant rs2476601 is
present in Crohn’s disease (Barrett et al., 2008). However, in
Crohn’s disease, it plays a complete opposite role to that in
T1D (Barrett et al., 2008). The alteration in PTPN22 expression
levels and its dysfunction can have deleterious or beneficial
effects depending on the mechanism involved. Normally, the
intestinal immune system is usually tightly controlled by an
existing balance of pro-inflammatory and anti-inflammatory
cytokines. Patients suffering from IBD have a disturbed balance
with more pro-inflammatory cytokines present. Crohn’s patients
have a reduced expression of PTPN22 in intestinal tissues.
Spalinger et al. showed that PTPN22 expression regulates
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intracellular signaling as induced by IFNγ in human monocytes
(Spalinger et al., 2013b). Studies have shown that knocking
down the PTPN22 gene alters the activation of inflammatory
signal transducers and increases the secretion of Th17-related
inflammatory mediators. By this mechanism, genetic variants
may induce pathogenesis of Crohn’s disease by prompting Th17
vs Th1 differentiation (Spalinger et al., 2013b). The decrease of
PTPN22 expression in Crohn’s disease could be because TNFα
and IL-1β both decrease its expression significantly and thus, play
a role in its pathogenesis (Spalinger et al., 2013b). Spalinger et al.
also found that the loss of PTPN22 protein function results in
increased p38-MAPK but reduces STAT1 and STAT3 signaling
(Spalinger et al., 2013b). This leads to increase levels of IL-6
and IL-17 secretion, and decrease expression and secretion of
T-bet, ICAM-1, MCP-1, IL-2, IL-8, and IL-12p40. The reduced
PTPN22 levels contribute to increased levels of IL-6 found
in Crohn’s disease. Also, p38 activation and IL-6 secretion by
antigen presenting cells play a huge role in differentiation of
CD4+ T cells into Th17 cells, which induces Crohn’s disease
pathogenesis (Spalinger et al., 2013b). The mechanism behind
how PTPN22 genetic variants are associated with Crohn’s disease
need to be further elucidated.
The function of the PTPN22 gene in other signaling pathways
is not very clear, but some studies have shown that it interferes
with pathways induced by components of bacteria and it fine
tunes signal cascade downstream of NOD2. NOD2 signaling is
controlled by PTPN22 expression and loss of it causes monocytes
to be reactive toward bacterial components. This results in
autophagy, which is increased in human and mouse cells
by MDP (muramyl-dipeptide)-mediated mechanism (Spalinger
et al., 2013a), further explaining association of this risk locus
with IBD. PTPN22 plays an important role in cytokine secretion
balance, which is crucial for activation and regulation of the
immune system (Spalinger et al., 2013b). Mutations of PTPN22
not only will lead to cytokine imbalance, but it can also lead
to T cells and B cells losing their ability to recognize self-
antigens from foreign antigens. These imbalances can lead to the
destruction of tissues (pancreatic for T1D patients and intestinal
for Crohn’s disease patients), which can become disastrous
in the body.
CONCLUSION
GWAS have played a key role in the discovery of important
genes associated with diseases of unknown etiology. The protein
tyrosine phosphatase genes, PTPN2 and PTPN22, are of vital
importance to both T1D and Crohn’s disease. Several other
genes such as ORMDL3 and IL-10 have also been associated
with both T1D and Crohn’s disease (Barrett et al., 2008; Qiu
et al., 2014). This indicates that these categorized autoimmune
diseases have common genetic predisposition that leads to the
manifestation of their pathogenesis by different mechanisms or
multiple pathways after exposure to environmental cues. Further
research is needed to understand more about the actual cascade
that occurs in the body and the mechanisms involved, as it is
crucial to finding an effective treatment to deal with such diseases.
A possible suggestion for future studies is to perform a large-scale
GWAS investigation to estimate the incidence of SNP’s in PTPN2
and PTPN22 in patients diagnosed with both T1D and Crohn’s
disease.
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